Share

Rise of the Machines: Artificial Intelligence in Healthcare

Artificial intelligence – once only found in a Steven Spielberg movie – is being adopted by the healthcare industry more and more from improving diabetes outcomes to reducing unnecessary thyroid surgeries. As these technologies improve, clinicians will soon have yet another ally to individualize patient care. Artificial intelligence. Machine learning. Those very phrases stir up...
Share

Positive Top-Line Results Announced from the Pivotal Phase 3 SONICS Study of Levoketoconazole for the Treatment of Endogenous Cushing’s Syndrome

Positive top-line results this week were announced from the multinational, pivotal Phase 3 SONICS study evaluating levoketoconazole for the treatment of endogenous Cushing’s syndrome. Strongbridge Biopharma is marketing the drug as RECORLEV™ . The open-label, single-arm SONICS study achieved statistical significance of its pre-specified primary endpoint, with 30 percent of patients achieving normalization of mean urinary...
Share

EndoGear: Laboratory Glassware Washers

Labconco SteamScrubber® 33 Now available in a new height of 33”, the SteamScrubber Glassware Washer fits beneath lower countertops. SteamScrubbers feature stainless steel top and bottom racks that accommodate basket inserts to hold a wide variety of glassware shapes and sizes, primarily beakers. Specialized inserts for petri dishes, culture tubes, and small utensils enhance the...
Share

ENDO 2018: Wearable Heart Rate Monitor Could Signal Low Blood Sugar in Type 1 Diabetes

A wearable medical patch measuring the beat-to-beat variation in heart rate is a promising device for the early detection of hypoglycemia, or low blood sugar, in type 1 diabetes, according to the researchers who tested the new monitor. Results of their preliminary study were presented Saturday at ENDO 2018, the Endocrine Society’s 100th annual meeting...
Share

FDA Approves New Continuous Glucose Monitoring System with Predictive Algorithm Technology

The U.S. Food and Drug Administration (FDA) has approved a new continuous glucose monitoring (CGM) system for people with diabetes ages 14 to 75 years. Medtronic is marketing the system as Guardian Connect, the first smart standalone CGM system to help people with diabetes stay ahead of high and low glucose events. The Guardian Connect...
Share

Canagliflozin Significantly Reduces the Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease

Late-breaking exploratory analysis from the CANVAS Program presented at the American College of Cardiology’s 67th Annual Scientific Session The results of  recent analysis showed that canagliflozin significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk. This exploratory analysis from...